Saving money on the PBS: ranibizumab or bevacizumab for neovascular macular degeneration?-Reference-Cited by-同舟云学术

Saving money on the PBS: ranibizumab or bevacizumab for neovascular macular degeneration?

Published:2011-06 Issue:11 Volume:194 Page:567-568
ISSN:0025-729X
Container-title:Medical Journal of Australia
language:en
Short-container-title:Medical Journal of Australia

Author:

Harvey Ken J¹,Day Richard O²,Campbell William G³,Lipworth Wendy⁴

Affiliation:

1. School of Public Health, La Trobe University, Melbourne, VIC.

2. St Vincent's Hospital and University of New South Wales, Sydney, NSW.

3. Royal Victorian Eye and Ear Hospital, Melbourne, VIC.

4. Australian Institute of Health Innovation, University of New South Wales, Sydney, NSW.

Publisher

AMPCo

Subject

General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.5694/j.1326-5377.2011.tb03105.x

Reference11 articles.

1. RoxonN.Opening address to Consumers Health Forum PBS Summit 29 Apr 2011.http://www.hirc.health.gov.au/internet/ministers/publishing.nsf/Content/F2D512F124949662CA257881001FC9AD/$File/nrsp290411.pdf(accessed May 2011).

2. Vision loss in Australia

3. Resolution of subretinal haemorrhage and fluid after intravitreal bevacizumab in aggressive peripapillary subretinal neovascularization

4. Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration

5. Intravitreal Bevacizumab and Ranibizumab for Age-Related Macular Degeneration

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bevacizumab for blinding eye disease – is it time for the PBS to list for off-label use?;Australian Health Review;2022-03-23

2. Time to rethink our approach to the Pharmaceutical Benefits Scheme (PBS) listing of medicines: the case of pregabalin;Australian Health Review;2021

3. Editorial: The challenge of costly drugs;Australian Prescriber;2016-06-01

4. Pharmacokinetic and Pharmacodynamic Properties of Anti-VEGF Drugs After Intravitreal Injection;Current Drug Metabolism;2015-10-28

5. Survey of Victorian ophthalmologists who use ranibizumab to treat age-related macular degeneration: to identify current practice and modifiable risk factors relevant to post-injection endophthalmitis;Clinical & Experimental Ophthalmology;2014-10-02